Axsome Therapeutics, Inc. (NASDAQ:AXSM) Stock Holdings Lifted by Moody Aldrich Partners LLC

Moody Aldrich Partners LLC increased its stake in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 38.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 62,339 shares of the company's stock after buying an additional 17,201 shares during the period. Axsome Therapeutics comprises 1.5% of Moody Aldrich Partners LLC's portfolio, making the stock its 16th largest holding. Moody Aldrich Partners LLC owned 0.13% of Axsome Therapeutics worth $7,271,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. NBC Securities Inc. purchased a new stake in shares of Axsome Therapeutics in the first quarter valued at about $31,000. Raiffeisen Bank International AG purchased a new stake in shares of Axsome Therapeutics in the fourth quarter valued at about $51,000. Assetmark Inc. acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $52,000. Aquatic Capital Management LLC acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $76,000. Finally, GF Fund Management CO. LTD. acquired a new position in shares of Axsome Therapeutics in the fourth quarter valued at approximately $86,000. Hedge funds and other institutional investors own 81.49% of the company's stock.

Axsome Therapeutics Stock Up 2.0%

Shares of AXSM stock traded up $2.06 on Monday, hitting $107.50. The stock had a trading volume of 570,536 shares, compared to its average volume of 668,793. The firm has a market capitalization of $5.29 billion, a price-to-earnings ratio of -18.63 and a beta of 0.46. The stock's 50 day moving average is $106.63 and its 200-day moving average is $107.80. The company has a debt-to-equity ratio of 3.48, a quick ratio of 1.96 and a current ratio of 2.03. Axsome Therapeutics, Inc. has a 52-week low of $72.21 and a 52-week high of $139.13.

Insider Buying and Selling at Axsome Therapeutics

In other Axsome Therapeutics news, COO Mark L. Jacobson sold 25,000 shares of the stock in a transaction on Monday, June 9th. The shares were sold at an average price of $110.44, for a total transaction of $2,761,000.00. Following the transaction, the chief operating officer directly owned 5,783 shares in the company, valued at $638,674.52. This represents a 81.21% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, General Counsel Hunter R. Murdock sold 7,500 shares of the stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $100.26, for a total transaction of $751,950.00. The disclosure for this sale can be found here. Insiders have sold 93,437 shares of company stock worth $9,834,215 in the last ninety days. 22.40% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on AXSM shares. HC Wainwright reissued a "buy" rating and issued a $180.00 price objective on shares of Axsome Therapeutics in a research report on Tuesday, June 10th. Jefferies Financial Group started coverage on shares of Axsome Therapeutics in a research report on Monday, April 7th. They set a "buy" rating and a $200.00 price target for the company. Wells Fargo & Company reaffirmed an "overweight" rating and set a $165.00 price target (up previously from $160.00) on shares of Axsome Therapeutics in a research report on Tuesday, May 6th. Mizuho upped their price target on shares of Axsome Therapeutics from $212.00 to $216.00 and gave the stock an "outperform" rating in a research report on Thursday, March 27th. Finally, Morgan Stanley started coverage on shares of Axsome Therapeutics in a research report on Thursday. They set an "overweight" rating and a $190.00 price target for the company. One research analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Axsome Therapeutics presently has a consensus rating of "Buy" and an average price target of $172.33.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.